Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | PLD1 | Q13393 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7781191 | 0.93 | KDM4E (0.52) | KDM1AHDAC6SIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL8989699 | 0.92 | PLD1 (0.56) | KDM1AHDAC6PLD1CD274HTR2C | |
| SCHEMBL7774077 | 0.92 | PLD1 (0.53) | KDM1AHDAC6PLD1CD274 | |
| SCHEMBL7778696 | 0.88 | PLD1 (0.50) | PLD1SLC6A2SLC6A4 | |
| SCHEMBL7781108 | 0.85 | PLD1 (0.53) | KDM1AHDAC6PLD1CD274 | |
| SCHEMBL7781120 | 0.85 | CCR3 (0.53) | SIGMAR1PLD1SLC6A2SLC6A4 | |
| SCHEMBL8989753 | 0.85 | CCR3 (0.50) | PLD1 | |
| SCHEMBL8989765 | 0.85 | SIGMAR1 (0.58) | SIGMAR1SLC6A2SLC6A4 | |
| SCHEMBL7817609 | 0.84 | HTR1A (0.46) | PLD1CD274SLC6A4 | |
| SCHEMBL7817813 | 0.83 | HTR2C (0.49) | PLD1HPGDHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1133293-A1 | USE OF N-SUBSTITUTED AZABICYCLOALKANE DERIVATIVES FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM | BASF AKTIENGESELLSCHAFT (DE) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000030639-A1 | USE OF N-SUBSTITUTED AZABICYCLOALKANE DERIVATIVES FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM | BASF AKTIENGESELLSCHAFT (DE) | 2000-06-02 | — | — | WO | disclosed |
| EP-0646110-B1 | N-SUBSTITUTED 3-AZABICYCLO[3.2.0]HEPTANE DERIVATIVES USEFUL AS NEUROLEPTIC AGENTS | BASF AG (DE) | 1996-10-23 | — | — | EP | disclosed |
| US-5521209-A | N-substituted azabicyclo[3.2.0]heptane derivatives as neuroleptics, the preparation and use thereof | BASF AKTIENGESELLSCHAFT (DE) | 1996-05-28 | — | — | US | disclosed |
| EP-0646110-A1 | N-SUBSTITUED 3-AZABICYCLO 3.2.0]HEPTANE DERIVATIVES USEFUL AS NEUROLEPTIC AGENTS ETC. | BASF AG (DE) | 1995-04-05 | — | — | EP | disclosed |
| WO-1994000431-A1 | N-SUBSTITUED 3-AZABICYCLO[3.2.0]HEPTANE DERIVATIVES USEFUL AS NEUROLEPTIC AGENTS ETC. | BASF AKTIENGESELLSCHAFT (DE) | 1994-01-06 | — | — | WO | disclosed |